ARHGDIB and prostate cancer: One notable exception was prostate cancer in which neither of the PGCC signatures but rather the 5-gene core signature of late progeny (FN1, INPP5D, ITGB4, ARHGDIB, IFIT1) was significantly predictive of outcomes (Fig. S4).